Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents
J Psychopharmacol. 2008-02-28; 22(5): 511-521
DOI: 10.1177/0269881107083836
Lire sur PubMed
1. J Psychopharmacol. 2008 Jul;22(5):511-21. doi: 10.1177/0269881107083836. Epub
2008 Feb 28.
Comparative effects of the dopaminergic agonists piribedil and bromocriptine in
three different memory paradigms in rodents.
Marighetto A(1), Valerio S, Philippin JN, Bertaina-Anglade V, Drieu la Rochelle
C, Jaffard R, Morain P.
Author information:
(1)Centre de Neurosciences Intégratives et Cognitives, CNRS UMR 5228, Université
de Bordeaux 1, Talence, France.
The potential memory-enhancing properties of two dopamine agonists currently used
in patients with Parkinson’s disease, piribedil (1, 10 mg/kg/day, subcutaneously)
and bromocriptine (5 mg/kg/day, subcutaneously), were evaluated in three
experiments. Although piribedil (10 mg/kg) and bromocriptine equally enhanced
spontaneous object recognition in young adult rats (experiment A), only piribedil
displayed beneficial effects against aging-related memory impairments in two
radial-maze experiments in mice. First (experiment B), a two-stage paradigm of
spatial discrimination was used to assess relational/declarative memory in aged
mice; piribedil (1 and 10 mg/kg) selectively and significantly improved the
performances of aged mice in the critical tests for relational/declarative
memory, whereas bromocriptine had no effect. Second, in a novel working memory
task (experiment C), vehicle- or bromocriptine-treated aged mice displayed,
compared with (vehicle) younger controls, a severe and persistent deficit in
short-term retention of successive arm-visits, performing close to chance
whichever the retention interval. Performances of piribedil (10 mg/kg) group
remarkably improved across testing-days and reached young adults’ level. The
restoration of specific mnemonic impairments, in aged mice, highlights the
memory-enhancing properties of piribedil. The efficacy of this drug in treating
cognitive impairment of Parkinson’s disease should now be assessed in more
specific models.This work was published in an abstract form: ECNP Abstracts, 2005
(P8060 & P8065).
DOI: 10.1177/0269881107083836
PMID: 18308794 [Indexed for MEDLINE]